European Journal of Clinical Pharmacology

, Volume 67, Issue 8, pp 759–766 | Cite as

A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis

Review Article



To evaluate the therapeutic effects of TNF-α blockers on ulcerative colitis (UC) and their safety.


Randomized controlled trials (RCTs) of TNF-α blockers for treatment of UC were retrieved from databases. Heterogeneity test was performed on all data to select effects models. Finally, sensitivity analysis was carried out, and a funnel plot was drawn to evaluate publication bias.


A total of nine RCTs conformed to the inclusion criteria. Of 1,226 patients with UC, 806 were given a TNF-α blocker, and 420 were given placebo or other drugs as control. Infliximab was used in eight papers and adalimumab in one paper. Placebo was used in seven papers and hormones in two papers. Short-term response, short-term relief, long-term response, and long-term relief were better in the TNF-α blocker group than in the control group (P < 0.05). TNF-α blockers decreased the colectomy rate (P < 0.05). There were no significant differences in mucosal healing and quality of life between the two groups (P > 0.05). The rates of adverse reactions were similar in the two groups (P > 0.05), but the rate of severe adverse reactions was significantly lower in the TNF-α blocker group than in the control group (P < 0.05). The funnel plot of each parameter was symmetrical with the lower part broader than the upper.


TNF-α blockers have better therapeutic effects on moderate or severe UC, which shows little response to conventional therapy. TNF-α blockers can induce short-term response, maintain long-term clinical response and clinical relief, and decrease the colectomy rate and the severe adverse reaction rate, but they fail to improve quality of life and mucosal healing.


Ulcerative colitis Tumor necrosis factor-α blocker Meta-analysis Therapeutic effects 


  1. 1.
    Lakatos PL (2006) Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 12:6102–6108PubMedGoogle Scholar
  2. 2.
    Kornbluth A, Sachar DB (2004) Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 99:1371–1385PubMedCrossRefGoogle Scholar
  3. 3.
    Carter MJ, Lobo AJ, Travis SP (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53(Suppl 5):V1–V16PubMedCrossRefGoogle Scholar
  4. 4.
    Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705–1709PubMedCrossRefGoogle Scholar
  5. 5.
    Rahimi R, Nikfar S, Abdollahi M (2007) Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 13:I13–I118Google Scholar
  6. 6.
    Lawson MM, Thomas AG, Akobeng AK (2006) Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3:CD005112PubMedGoogle Scholar
  7. 7.
    Ford AC, Sandborn WJ, Khan KJ et al (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106:644–659Google Scholar
  8. 8.
    Sands BE, Tremaine WJ, Sandborn WJ et al (2001) Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7:83–88PubMedCrossRefGoogle Scholar
  9. 9.
    Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52:998–1002PubMedCrossRefGoogle Scholar
  10. 10.
    Armuzzi A, De Pascalis B, Lupascu A et al (2004) Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 8:231–233PubMedGoogle Scholar
  11. 11.
    Ochsenkuhn T, Sackmann M, Goke B (2004) Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 16:1167–1171PubMedCrossRefGoogle Scholar
  12. 12.
    Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476PubMedCrossRefGoogle Scholar
  13. 13.
    Jarnerot G, Hertervig E, Friis-Liby I et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811PubMedCrossRefGoogle Scholar
  14. 14.
    Feagan BG, Reinisch W, Rutgeerts P et al (2007) The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 102:794–802PubMedCrossRefGoogle Scholar
  15. 15.
    Sandborn WJ, Rutgeerts P, Feagan BG et al (2009) Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137:1250–1260PubMedCrossRefGoogle Scholar
  16. 16.
    Reinisch W, Sandborn WJ, Hommes DW et al (2010) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. Gastroenterology 138(suppl 1):114–115Google Scholar
  17. 17.
    Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12(Suppl 1):S3–S9PubMedCrossRefGoogle Scholar
  18. 18.
    Mueller C (2002) Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 105:1–8PubMedCrossRefGoogle Scholar
  19. 19.
    Raddatz D, Bockemuhl M, Ramadori G (2005) Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17:547–557PubMedCrossRefGoogle Scholar
  20. 20.
    Watanabe C, Miura S, Hokari R et al (2002) Spatial heterogeneity of TNF-alpha-induced T cell migration to colonic mucosa is mediated by MAdCAM-1 and VCAM-1. Am J Physiol Gastrointest Liver Physiol 283:G1379–G1387PubMedGoogle Scholar
  21. 21.
    Irving PM, Macey MG, Feakins RM et al (2008) Platelet-leucocyte aggregates form in the mesenteric vasculature in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 20:283–289PubMedCrossRefGoogle Scholar
  22. 22.
    Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRefGoogle Scholar
  23. 23.
    Targan SR, Feagan BG, Fedorak RN et al (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132:1672–1683PubMedCrossRefGoogle Scholar
  24. 24.
    Sandborn WJ, Feagan BG, Stoinov S et al (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357:228–238PubMedCrossRefGoogle Scholar
  25. 25.
    Regueiro M, Curtis J, Plevy S (2006) Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 40:476–481PubMedCrossRefGoogle Scholar
  26. 26.
    Probert CS, Hearing SD, Schreiber S et al (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52:998–1002PubMedCrossRefGoogle Scholar
  27. 27.
    Rutter M, Saunders B, Wilkinson K et al (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:451–459PubMedCrossRefGoogle Scholar
  28. 28.
    Rutter MD, Saunders BP, Wilkinson KH et al (2004) Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53:1813–1816PubMedCrossRefGoogle Scholar
  29. 29.
    Rosh JR, Gross T, Mamula P et al (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 13:1024–1030PubMedCrossRefGoogle Scholar
  30. 30.
    Leung Y, Hanauer SB (2009) Conventional treatment in inflammatory bowel disease—recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol 33(Suppl 3):S202–S208PubMedCrossRefGoogle Scholar
  31. 31.
    Fan W, Maoqing W, Wangyang C et al (2011) Relationship between the polymorphism of tumor necrosis factor-α-308 G > A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Eur J Hum Genet 19:432–437PubMedCrossRefGoogle Scholar
  32. 32.
    Lu Z, Chen L, Li H et al (2008) Effect of the polymorphism of tumor necrosis factor-alpha-308 G/A gene promoter on the susceptibility to ulcerative colitis: a meta-analysis. Digestion 78:44–51PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Gastroenterology, the First Affiliated HospitalZhejiang Chinese Medical UniversityHangzhouChina
  2. 2.Hangzhou CityChina

Personalised recommendations